Evidence map›Paper›PMID 40634934›Full record

ArticleBMC pulmonary medicine2025

Activity and mechanism of naringin in the treatment of post-infectious cough.

Yinghan Chen, Dong Wang, Meng Song, Weiqi Pan, Wenda Guan, Zifeng Yang, Shan Zhong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yinghan Chen *State Key Laboratory of Respiratory Disease, Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510080, China.
Dong Wang *School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Meng SongState Key Laboratory of Respiratory Disease, Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510080, China.
Weiqi PanState Key Laboratory of Respiratory Disease, Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510080, China.
Wenda GuanState Key Laboratory of Respiratory Disease, Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510080, China.
Zifeng YangState Key Laboratory of Respiratory Disease, Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510080, China. jeffyah@163.com.
Shan ZhongState Key Laboratory of Respiratory Disease, Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510080, China. zhong-shan@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore activity and mechanism of naringin in the treatment of PIC (Post-Infectious Cough) by virtue of network pharmacology and animal studies.

methodsThe targets associated with naringin were obtained from the SwissTargetPrediction and Super-PRED databases. Disease-related targets were collected from GeneCards and OMIM (Online Mendelian Inheritance in Man). Venny was utilized to identify the overlapping targets between naringin and the disease. PPI (Protein-Protein Interaction) networks for disease-related targets were constructed using STRING and Cytoscape 3.10.1. GO (Gene Ontology) functional annotation and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analyses were performed with Metascape. Molecular docking between key targets and naringin was conducted using AutoDock Vina. In the animal experiments, PIC models were established in guinea pigs via intranasal inoculation with A/PR/8 virus, and cough frequency was measured after citric acid-induced coughing. Morphological changes in lung tissue and airways were assessed using the HE (Hematoxylin-Eosin) staining method. The relative expression levels of IL-8 (Interleukin-8), IL-1β (Interleukin-1β), TNF-α (Tumor Necrosis Factor-Alpha), and NF-κB p65 (Nuclear Factor Kappa-B p65 Subunit) mRNA were analyzed by RT-qPCR (Reverse Transcription Quantitative Polymerase Chain Reaction). SOD (Superoxide Dismutase) activity in lung tissue was measured using a colorimetric assay.

resultsAfter screening, naringin may contribute to the treatment of post-infectious cough by targeting proteins expressed by core genes such as HSP90AA1 (HSP 90-Alpha), TLR4 (Toll-like Receptor 4), MTOR (Mechanistic Target of Rapamycin), HIF1A (Hypoxia-Inducible Factor Alpha), and NF-κB1 (Nuclear Factor Kappa-B Subunit 1). KEGG enrichment analysis revealed involvement in pathways including the HIF-1 (Hypoxia-Inducible Factor 1) signaling pathway and the PD-L1 (Programmed Death-Ligand 1) expression and PD-1 (Programmed Cell Death Protein 1) checkpoint pathway in cancer. Molecular docking results indicated that naringin exhibited strong binding affinity with HSP90AA1, TLR4, MTOR, HIF1A, NF-κB1, NOS3 (Nitric Oxide Synthase 3), and GRB2 (Growth Factor Receptor-Bound Protein 2). In animal experiments, compared to the normal group, guinea pigs in the model group exhibited a significantly higher number of coughs, pronounced lung tissue hyperplasia, and inflammatory cell infiltration. Additionally, the relative expression of IL-8, IL-1β, TNF-α, and NF-κB p65 mRNA was significantly increased, while lung tissue SOD activity was decreased. Treatment with naringin significantly reduced the number of coughs, attenuated pathological changes in lung tissue, lowered the lung index, decreased the relative expression of IL-8, IL-1β, TNF-α, and NF-κB p65 mRNA, and significantly increased SOD activity in lung tissue compared to the model group.

conclusionNaringin shows therapeutic potential to alleviate PIC symptoms in a guinea pig model through anti-inflammatory and antioxidant mechanisms.

Indexed as

CoughFlavanonesAnimalsDisease Models, AnimalGuinea PigsLungMaleMolecular Docking SimulationProtein Interaction MapsSignal TransductionTumor Necrosis Factor-alphaFlavanonesnaringinTumor Necrosis Factor-alphaAnti-inflammatoryAntioxidantNaringinNetwork pharmacologyPost-infectious cough

Identifiers

PMID40634934
PMCPMC12243327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.